


# Supporting Efficient Biosimilar Implementation Through Thoughtful Tactical Execution\*



To ensure efficient biosimilar implementation, tactical execution should involve an implementation strategy including multidisciplinary collaboration among physicians and pharmacists, as well as other medical and administrative staff. Clear timelines and defined roles and responsibilities will help ensure smooth implementation execution.

As a key player involved in the financial decisions throughout biosimilar implementation, you can help to further support this process by ensuring various stakeholders within your organization take the necessary steps to execute important tactics for which they may be responsible.

## TACTICAL CONSIDERATIONS THAT COULD IMPACT REALIZED COST SAVINGS<sup>1-9</sup>

## MONITORING



### Managing Billing, Reimbursement, and the Payer Landscape<sup>1-6</sup>

- **Benefits verification team** to ensure workflow is in place for coverage and authorization and determine if PA process will be manual or automated<sup>1-4</sup>
- **GPOs** and/or **contracting team** to leverage available discounts for preferred biosimilar<sup>2,5,6</sup>



### Updating Systems/Inventory<sup>2,3,5,7,8</sup>

- **Pharmacists** and **HIT team** to add biosimilars to EHR and order sets and set preferred agent as default<sup>2,3,5</sup>
- **Procurement team** and **pharmacy** to update inventory management/purchasing systems to include biosimilar and ensure a reliable and consistent supply<sup>3,5,7,8</sup>



### Communicating Key Information<sup>1,3,5,7,9</sup>

- **Pharmacists** to lead education of **HCPs** and **office staff** on strategies to overcome barriers<sup>1,3,5,9</sup>
- **Pharmacists** and **HCPs** to educate **patients** and ensure access to patient education materials<sup>5,7</sup>



### Measuring and Providing Success<sup>1,5,8,10</sup>

- **MCOs, PBMs,** and **finance team** to provide performance, utilization, and financial-level reporting<sup>1,10</sup>
- **Pharmacists** and **prescribers** to monitor drug use evaluation outcomes and clinical experience<sup>1,8,10</sup>
- **Pharmacists** to engage in pharmacovigilance programs<sup>5</sup>


## COMMUNICATION ACROSS STAKEHOLDERS<sup>1,3,5</sup>

\*Biosimilar adoption processes and roles may vary by institution.

EHR=electronic health record; GPO=group purchasing organization; HCP=healthcare professional; HIT=health information technology; MCO=managed care organization; PA=prior authorization; PBM=pharmacy benefits manager.

# Pfizer Provides Support to Help With Seamless Biosimilar Integration for Your Practice, Hospital, or Health System

Resources are available to help practices, hospitals, and health systems integrate biosimilars through effective operational enablement, IT, monitoring, education, and communication.



EHR=electronic health record; IT=information technology; P&T=pharmacy and therapeutics committee.

For more information, please speak with your Pfizer representative and visit [PfizerBiosimilars.com](https://www.pfizer.com/biosimilars)

**References:** **1.** AMCP Partnership Forum: biosimilars—ready, set, launch. *J Manag Care Spec Pharm.* 2016;22(4):434-440. **2.** Komorny K, Roux R, Bartel S, et al. NCCN pharmacy directors forum recommendations on operationalizing the safe and efficient use of biosimilars in the clinical setting. <https://www.nccn.org/docs/default-source/clinical/nccn-pharmacy-directors-forum-white-paper-operationalizing-the-safe-and-efficient-use-of-biosimilars.pdf>. Accessed December 22, 2021. **3.** Villanueva MN, Davis JE, Sobocinski SM. Navigating uncharted waters: Developing a standardized approach for evaluating and implementing biosimilar products at a comprehensive cancer center. *Am J Health Syst Pharm.* 2021;78(3):249-260. **4.** American Medical Association. Tips to help physicians reduce the prior authorization burden in their practice. <https://www.ama-assn.org/media/7411/download>. Accessed February 7, 2022. **5.** Ventola CL. Evaluation of biosimilars for formulary inclusion: factors for consideration by P&T committees. *P T.* 2015;40(10):680-689. **6.** Boccia R, Jacobs I, Popovian R, de Lima Lopes G Jr. Can biosimilars help achieve the goals of US health care reform? *Cancer Manag Res.* 2017;9:197-205. **7.** Griffith N, McBride A, Stevenson JG, Green L. Formulary selection criteria for biosimilars: considerations for US health-system pharmacists. *Hosp Pharm.* 2014;49(9):813-825. **8.** Oskouei ST. Following the biosimilar breadcrumbs: when health systems and manufacturers approach forks in the road. *J Manag Care Spec Pharm.* 2017;23(12):1245-1248. **9.** Greene L, Singh RM, Carden MJ, Pardo CO, Lichtenstein GR. Strategies for overcoming barriers to adopting biosimilars and achieving goals of the Biologics Price Competition and Innovation Act: A survey of managed care and specialty pharmacy professionals. *J Manag Care Spec Pharm.* 2019;25(8):904-912. **10.** AMCP. Drug utilization review. <https://www.amcp.org/about/managed-care-pharmacy-101/concepts-managed-care-pharmacy/drug-utilization-review>. Accessed January 10, 2022.